Key Insights

Highlights

Treatment Research

2 treatments under study, led by Recombinant Human Papillomavirus 9valent Types 6 11 16 18 31 33 45 52 58 Vaccine Ecoli

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06866574Phase 3Active Not Recruiting

A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males

Showing all 1 trials

Research Network

Common Treatments

  • Recombinant Human Papillomavirus 9valent Types 6 11 16 18 31 33 45 52 58 Vaccine Ecoli1
  • Aluminum Adjuvant1

Active Sponsors

  • Xiamen Innovax Biotech Co., Ltd1
  • Xiamen University1

Top Investigators

Related Conditions

  • Anal Cancer1
  • Penileperineal Perianal Intraepithelial Neoplasia1
  • Genital Warts1
  • Anal Intraepithelial Neoplasia1

Activity Timeline